Disopyramide, used in obstructive hypertrophic cardiomyopathy (oHCM) for its negative inotropic properties mediated by its reduction in cytosolic calcium, has been recommended for decades as an option to relieve resistant obstruction. Aficamten is a selective cardiac myosin inhibitor that reduces hypercontractility directly by reducing myosin-actin interaction.
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy / Masri, Ahmad; Maron, Martin S.; Abraham, Theodore P.; Nassif, Michael E.; Barriales-Villa, Roberto; Bilen, Ozlem; Coats, Caroline J.; Elliott, Perry; Garcia-Pavia, Pablo; Massera, Daniele; Olivotto, Iacopo; Oreziak, Artur; Owens, Anjali Tiku; Saberi, Sara; Solomon, Scott D.; Tower-Rader, Albree; Heitner, Stephen B.; Jacoby, Daniel L.; Melloni, Chiara; Wei, Jenny; Sherrid, Mark V.. - In: JACC. HEART FAILURE. - ISSN 2213-1779. - ELETTRONICO. - (2025), pp. 1-43. [10.1016/j.jchf.2025.03.008]
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Olivotto, Iacopo
;
2025
Abstract
Disopyramide, used in obstructive hypertrophic cardiomyopathy (oHCM) for its negative inotropic properties mediated by its reduction in cytosolic calcium, has been recommended for decades as an option to relieve resistant obstruction. Aficamten is a selective cardiac myosin inhibitor that reduces hypercontractility directly by reducing myosin-actin interaction.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2213177925002434-main.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
696.1 kB
Formato
Adobe PDF
|
696.1 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
